For decades, scientists have known that mitochondria, the tiny powerhouses inside our cells, malfunction in Parkinson’s Disease. But the big question remained: Do failing mitochondria cause Parkinson’s, or are they simply collateral damage as brain cells die?
A new study from Gladstone Institutes, published in Science Advances, offers compelling evidence that mitochondrial dysfunction can initiate the onset of Parkinson’s Disease. Using a unique mouse model that mimics both rare inherited and common late-onset forms of Parkinson’s, researchers traced a step-by-step cascade:
- Mutations in a mitochondrial protein (CHCHD2) distort mitochondria and disrupt energy production.
- Cells switch to less efficient energy pathways, increasing oxidative stress.
- Reactive oxygen species accumulate, triggering the aggregation of alpha-synuclein, the hallmark protein found in Lewy bodies in Parkinson’s patients.
This sequence was confirmed in human brain tissue, strengthening the link between mitochondrial damage and disease progression. The findings suggest that targeting oxidative stress and boosting cellular energy could open new paths for treatment.
As research advances, the hope is clear: by protecting mitochondria, we may one day slow or stop Parkinson’s before it starts.